Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
度伐利尤单抗联合放化疗治疗不可切除的III期非小细胞肺癌的真实世界5年疗效
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2026.106070
Girard, N; Bar, J; Baas, P; Chouaid, C; Christoph, D C; Field, J K; Fietkau, R; Garassino, M C; Garrido Lopez, P; Gregorc, V; Haakensen, V D; Hiltermann, T J N; Kao, S; McDonald, F; Mornex, F; Moskovitz, M; Peters, S; Siva, S; Solomon, B; Qiao, Y; Anand, S; Chander, P; Shcherbakova, T; Diaz Perez, I; Filippi, A R